Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Santa Monica, CA
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Aurora, CO
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Atlanta, GA
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Boston, MA
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Detroit, MI
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
St Louis, MO
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
New York, NY
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Portland, OR
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated:  12/31/2015
mi
from
Brisbane,
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine
Status: Enrolling
Updated: 12/31/2015
mi
from
Brisbane,
Click here to add this to my saved trials
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)
Status: Enrolling
Updated:  1/8/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)
Status: Enrolling
Updated: 1/8/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/11/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/11/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/11/2016
University of California at Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/11/2016
University of California at Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/11/2016
Novartis Investigative Site
mi
from
Utrecht,
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/11/2016
Novartis Investigative Site
mi
from
Utrecht,
Click here to add this to my saved trials
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated:  1/11/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated: 1/11/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated:  1/11/2016
Wills Eye Hospital
mi
from
Philadelphia, PA
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated: 1/11/2016
Wills Eye Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated:  1/11/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated: 1/11/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
IL15-DC Vaccine in Patients With High Risk Melanoma - Exploratory Phase I/II Trial
Status: Enrolling
Updated:  1/12/2016
Baylor University Medical Center
mi
from
Dallas, TX
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
IL15-DC Vaccine in Patients With High Risk Melanoma - Exploratory Phase I/II Trial
Status: Enrolling
Updated: 1/12/2016
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Irvine, CA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
La Jolla, CA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Orange, CA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Aurora, CO
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Goshen, IN
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Goshen, IN
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Louisville, KY
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Marrero, LA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Marrero, LA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Baltimore, MD
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Easton, PA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Easton, PA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Knoxville, TN
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated:  1/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Status: Enrolling
Updated: 1/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Children's Hospital Oakland Research Institute
mi
from
Oakland, CA
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Children's Hospital Oakland Research Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
Click here to add this to my saved trials
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma
Status: Enrolling
Updated:  1/13/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma
Status: Enrolling
Updated: 1/13/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma
Status: Enrolling
Updated:  1/14/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma
Status: Enrolling
Updated: 1/14/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials